Lyell Immunopharma completed the transfer of LYL273 to its LyFE Manufacturing Center, which is expected to produce more than 1,200 CAR T-cell doses annually. The move supports continued Phase 1/2 enrollment, with additional clinical data and an End-of-Phase 1 FDA meeting expected in 2027.

Key Highlights

  • Lyell completed the technology transfer of LYL273 to its LyFE Manufacturing Center in Bothell, Washington.
  • The CARABiNER trial (NCT05319314) is a U.S. Phase 1/2 dose-escalation and dose-expansion study.
  • Additional clinical data and an End-of-Phase 1 FDA meeting are expected in 2027.

Lyell Immunopharma, Inc. (NASDAQ: LYEL) completed the technology transfer of LYL273 to its LyFE Manufacturing Center in Bothell, Washington, while updating the expected timing for additional trial data and an End-of-Phase 1 FDA meeting to 2027.

LYL273 Manufacturing Moves to LyFE

The trial, identified as CARABiNER (NCT05319314), is a U.S. Phase 1/2 dose-escalation and dose-expansion study.

Trial Enrollment Continues Into 2027

Enrollment continues as additional patients receive LYL273 made through the new process. The stated objective is to determine the recommended Phase 2 dose and refine the safety management plan, including prophylaxis and immune suppression. Additional clinical data and the End-of-Phase 1 FDA meeting are expected in 2027.